Follow
Stephen Clarke
Stephen Clarke
Professor of Medicine, University of Sydney and Medical Oncologist, RNSH and Genesis Care
Verified email at sydney.edu.au
Title
Cited by
Cited by
Year
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
LB Saltz, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
Journal of clinical oncology 26 (12), 2013-2019, 2008
39082008
Cancer-related inflammation and treatment effectiveness
CI Diakos, KA Charles, DC McMillan, SJ Clarke
The Lancet Oncology 15 (11), e493-e503, 2014
18792014
The systemic inflammation-based neutrophil–lymphocyte ratio: experience in patients with cancer
GJK Guthrie, KA Charles, CSD Roxburgh, PG Horgan, DC McMillan, ...
Critical reviews in oncology/hematology 88 (1), 218-230, 2013
16642013
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
Journal of clinical oncology 26 (12), 2006-2012, 2008
10882008
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ...
The lancet oncology 13 (12), 1225-1233, 2012
6412012
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
N Van Zandwijk, N Pavlakis, SC Kao, A Linton, MJ Boyer, S Clarke, ...
The Lancet Oncology 18 (10), 1386-1396, 2017
5882017
Clinical pharmacokinetics of docetaxel
SJ Clarke, LP Rivory
Clinical pharmacokinetics 36, 99-114, 1999
5721999
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer
W Chua, KA Charles, VE Baracos, SJ Clarke
British journal of cancer 104 (8), 1288-1295, 2011
5402011
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
MJ Proctor, DC McMillan, DS Morrison, CD Fletcher, PG Horgan, ...
British journal of cancer 107 (4), 695-699, 2012
5252012
Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial
BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ...
Journal of Clinical Oncology 36 (24), 2532, 2018
4562018
Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer
ET Morgan, KB Goralski, M Piquette-Miller, KW Renton, GR Robertson, ...
Drug Metabolism and Disposition 36 (2), 205-216, 2008
4412008
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE …
HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ...
The Lancet Oncology 18 (9), 1159-1171, 2017
3752017
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy
SCH Kao, N Pavlakis, R Harvie, JL Vardy, MJ Boyer, N van Zandwijk, ...
Clinical cancer research 16 (23), 5805-5813, 2010
3622010
Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review
EL Davis, B Oh, PN Butow, BA Mullan, S Clarke
The oncologist 17 (11), 1475-1481, 2012
3542012
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
British journal of cancer 105 (1), 58-64, 2011
3112011
Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis
QP Janssen, S Buettner, M Suker, BR Beumer, P Addeo, P Bachellier, ...
JNCI: Journal of the National Cancer Institute 111 (8), 782-794, 2019
2982019
Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial
B Oh, P Butow, B Mullan, S Clarke, P Beale, N Pavlakis, E Kothe, L Lam, ...
Annals of Oncology 21 (3), 608-614, 2010
2972010
Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy
KA Slaviero, SJ Clarke, LP Rivory
The lancet oncology 4 (4), 224-232, 2003
2922003
The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer
JCY Chan, DL Chan, CI Diakos, A Engel, N Pavlakis, A Gill, SJ Clarke
Annals of surgery 265 (3), 539-546, 2017
2912017
Diagnosis of gastrointestinal bleeding: A practical guide for clinicians
BSM Kim, BT Li, A Engel, JS Samra, S Clarke, ID Norton, AE Li
World journal of gastrointestinal pathophysiology 5 (4), 467, 2014
2872014
The system can't perform the operation now. Try again later.
Articles 1–20